Sophia M. Roush

Sophia M. Roush

Auto-generated profile, based on publicly available information

Sophia M. Roush

The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2018 in Leukemia
Verified
Journal Article
Closed access
PDF file
AEAnn-Kathrin Eisfeld
Ann-Kathrin Eisfeld
JKJessica Kohlschmidt
Jessica Kohlschmidt
KMKrzysztof Mrózek
Krzysztof Mrózek
JBJames S. Blachly
James S. Blachly
CWChristopher J. Walker
Christopher J. Walker
CBClara D. Bloomfield
Clara D. Bloomfield

5 June 2018 in Leukemia
Verified
Journal Article
Closed access
PDF file
AEAnn-Kathrin Eisfeld
Ann-Kathrin Eisfeld
JKJessica Kohlschmidt
Jessica Kohlschmidt
KMKrzysztof Mrózek
Krzysztof Mrózek
AMAlice Mims
Alice Mims
CWChristopher J. Walker
Christopher J. Walker
CBClara D. Bloomfield
Clara D. Bloomfield

7 November 2017 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
HHHuiling He
Huiling He
WLWei Li
Wei Li
SLSandya Liyanarachchi
Sandya Liyanarachchi
YWYanqiang Wang
Yanqiang Wang
LYLianbo Yu
Lianbo Yu
ACAlbert De la Chapelle
Albert De la Chapelle
Context Previous genome-wide association studies (GWAS) have shown that SNP rs2439302 in chromosome 8p12 is significantly associated with papillary thyroid carcinoma (PTC) risk and dysregulated NRG1 expression. The underlying mechanisms remain to be discovered. Objective To evaluate the expression of NRG1 isoforms, candidate functional variants, and potential genes downstream of NRG1 in thyroid tissue. Methods Quantitative RT-PCR was applied for gene expression analysis. SNaPshot assay, haplotype and computer analyses were performed to evaluate candidate functional variants. Other functional assays (ChIP, luciferase assay, siRNA knockdown, and RNA-Seq) were performed. Results Three NRG1 isoforms (NM_004495, NM_013958, and NM_001160008) tested were relatively highly expressed in thyroid tissue. The expression levels of the three isoforms were significantly correlated with the genotypes of rs2439302. A DNA block of ∼32 kb containing the risk G allele of rs2439302 was revealed, harboring multiple candidate functional variants. ChIP assay for active chromatin markers indicated at least nine regions in the DNA block showing strong H3Kme1 and H3K27Ac signals in thyroid tissue. Luciferase reporter assays revealed differential allelic activities associated with seven SNPs. Knocking down NRG1 in primary thyroid cells revealed downstream or interacting genes related to NRG1. Conclusions Our data suggest a role for transcriptional regulation of NRG1 in the predisposition to PTC.

21 August 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MDMegan C. Duggan
Megan C. Duggan
ASAndrew R. Stiff
Andrew R. Stiff
MBMaryam Bainazar
Maryam Bainazar
KRKelly Regan
Kelly Regan
GSGonzalo N. Olaverria Salavaggione
Gonzalo N. Olaverria Salavaggione
WCWilliam E Carson
William E Carson
Significance: This study indicates that one of the isoforms of NRAS, specifically NRAS isoform 2, plays a role in BRAF inhibitor resistance by facilitating alternative survival signaling through the PI3K pathway in the presence of MAPK pathway inhibition. Targeting NRAS isoform 2 may be a beneficial treatment strategy in the prevention and management of BRAF inhibitor resistance in melanoma.

18 November 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MLMalori A. Lankenau
Malori A. Lankenau
RPRavi Patel
Ravi Patel
SLSandya Liyanarachchi
Sandya Liyanarachchi
SMSophia E. Maharry
Sophia E. Maharry
KHKevin W. Hoag
Kevin W. Hoag
ACAlbert De la Chapelle
Albert De la Chapelle
Significance: Activating mutations in the B-Raf proto-oncogene serine/threonine kinase ( BRAF ) gene occur in many tumor types, the highest incidence being in malignant melanoma and papillary thyroid carcinoma. In patients with BRAF mutations tumor progression is more rapid than in patients without these mutations. Therapeutic strategies presently aim at inhibiting BRAF resulting in slower tumor progression; however, lasting remission is rarely accomplished. In this paper we identify the oncomiR-3151 as a downstream effector of mutated BRAF. MicroRNA-3151 (miR-3151) targets TP53 and other members of the TP53 pathway resulting in its inhibition. Simultaneous inhibition of BRAF and miR-3151 potentiates the effects on tumor cell growth. These data establish a link between mutated BRAF and the TP53 pathway, allowing novel therapeutic approaches to be considered.

31 August 2016 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SMSophia E. Maharry
Sophia E. Maharry
CWChristopher J. Walker
Christopher J. Walker
SLSandya Liyanarachchi
Sandya Liyanarachchi
SMSujay Mehta
Sujay Mehta
MPMitra Patel
Mitra Patel
AEAnn-Kathrin Eisfeld
Ann-Kathrin Eisfeld
Chromosomal aberrations and multiple genome-wide association studies (GWAS) have established a major hematopoietic quantitative trait locus in chromosome 6q23.3. The locus comprises an active enhancer region, in which some of the associated SNPs alter transcription factor binding. We now identify miR-3662 as a new functional driver contributing to the associated phenotypes. The GWAS SNPs are strongly associated with higher miR-3662 expression. Genome editing of rs66650371, a three-base-pair deletion, suggests a functional link between the SNP genotype and the abundance of miR-3662. Increasing miR-3662′s abundance increases colony formation in hematopoietic progenitor cells, particularly the erythroid lineage. In contrast, miR-3662 is not expressed in acute myeloid leukemia cells, and its overexpression has potent antileukemic effects in vitro and in vivo. Mechanistically, miR-3662 directly targets NF-κB–mediated transcription. Thus, miR-3662 is a new player of the hematopoietic 6q23.3 locus. Significance: The characterization of miR-3662 has identified a new actor in the prominent hematopoietic quantitative trait locus in chromosome 6q23.3. The mechanistic insights into miR-3662′s function may reveal novel or only partially known pathways for normal and malignant hematopoietic cell proliferation. Cancer Discov; 6(9); 1036–51. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 932